Holen Sie sich die Stockscreener-App
18.23
0.22%
0.04
Handel nachbörslich:
18.05
-0.18
-0.99%
Schlusskurs vom Vortag:
$18.19
Offen:
$18.19
24-Stunden-Volumen:
575.10K
Relative Volume:
0.54
Marktkapitalisierung:
$1.34B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-230.32M
KGV:
-5.1703
EPS:
-3.5259
Netto-Cashflow:
$-196.04M
1W Leistung:
+11.36%
1M Leistung:
+6.11%
6M Leistung:
+32.10%
1J Leistung:
-53.17%
1-Tages-Spanne:
$17.94
$18.58
1-Wochen-Bereich:
$16.53
$18.75
52-Wochen-Spanne:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.23 | 1.34B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Hochstufung | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | Herabstufung | Goldman | Neutral → Sell |
| 2026-01-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-11-03 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-09-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-09-30 | Herabstufung | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Herabstufung | Stifel | Buy → Hold |
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - MSN
How Moonlake Immunotherapeutics (MLTX) Affects Rotational Strategy Timing - Stock Traders Daily
MoonLake clears a key regulatory hurdle, and shares rocket - MSN
Should FDA Alignment on Sonelokimab’s HS Label Strategy Require Action From MoonLake Immunotherapeutics (MLTX) Investors? - simplywall.st
MLTX stock soars overnight after FDA backs skin drug filing — analyst sees over 300% upside on 'best-in-class' label - MSN
MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors? - Kavout
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
MoonLake (MLTX) shares gain after positive FDA meeting on sonelokimab filing - MSN
MLTX Technical Analysis | Trend, Signals & Chart Patterns | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive FDA Pre BLA Outcome For Sonelokimab - simplywall.st
FDA aligns with MoonLake on lead drug submission plans, stock soars - MSN
Cormorant Asset Management and Bihua Chen report 6.25% stake in MoonLake (MLTX) - Stock Titan
(MLTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
Insider Sell Alert: Matthias Bodenstedt Sells Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
MoonLake Immunotherapeutics (MLTX) CFO logs pre-planned sale of 13,653 shares - Stock Titan
Equities Analysts Set Expectations for MLTX Q1 Earnings - MarketBeat
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $45 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Is Up 7.3% After FDA Aligns on Sonelokimab BLA Pathway - Yahoo Finance
Needham raises Moonlake stock price target to $30 on BLA filing plans - Investing.com
Needham raises Moonlake stock price target to $30 on BLA filing plans By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained - TipRanks
Update: MoonLake Immunotherapeutics Q1 Net Loss Widens - Moomoo
MoonLake Gains FDA Clearance for Sonelokimab Hidradenitis Suppurativa Label - The Clinical Trial Vanguard
MoonLake price target raised to $45 from $40 at H.C. Wainwright - TipRanks
Down-But-Not-Out Biotech Rockets On A Key FDA Decision - Investor's Business Daily
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $70 - 富途牛牛
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential - TipRanks
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moonlake Immunotherapeutics-Aktie (MLTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bodenstedt Matthias | Chief Financial Officer |
Apr 14 '26 |
Sale |
19.56 |
2,426 |
47,453 |
1,186,084 |
| Santos da Silva Jorge | Chief Executive Officer |
Apr 10 '26 |
Sale |
18.41 |
98,127 |
1,806,518 |
2,976,766 |
| Santos da Silva Jorge | Chief Executive Officer |
Apr 13 '26 |
Sale |
18.23 |
51,873 |
945,645 |
2,924,893 |
| Bodenstedt Matthias | Chief Financial Officer |
Apr 09 '26 |
Sale |
18.94 |
85,870 |
1,626,378 |
1,190,435 |
| Bodenstedt Matthias | Chief Financial Officer |
Apr 10 '26 |
Sale |
19.51 |
1,925 |
37,557 |
1,188,510 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):